Shared on 31 Oct 25
Fair value Increased 3.64%United Therapeutics' analyst price target has increased from approximately $493 to $511, as analysts cite strong Tyvaso revenue growth, robust product launches, and positive trial data. These factors support improved profit expectations and future growth prospects.
Shared on 17 Oct 25
Fair value Increased 1.67%Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
The analyst price target for United Therapeutics has increased modestly by approximately $8 to $492.85. Analysts cite greater confidence in the company’s future sales and profit margins following recent positive clinical trial outcomes and updated research coverage.
Shared on 03 Oct 25
Fair value Increased 3.85%Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
United Therapeutics' analyst price target has climbed significantly, rising from approximately $467 to nearly $485 per share. Analysts cite robust Phase 3 results for Tyvaso in idiopathic pulmonary fibrosis and a strengthened outlook for future sales growth.
Shared on 18 Sep 25
Fair value Increased 2.19%Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
Analysts raised their price target for United Therapeutics to $466.82, citing strong TETON-2 Phase 3 data for Tyvaso in IPF that de-risk future revenue, support peak sales projections, and heighten confidence in market exclusivity and regulatory approvals. Analyst Commentary Bullish analysts raised price targets significantly following strong Phase 3 TETON-2 data for Tyvaso in idiopathic pulmonary fibrosis (IPF), with the drug meeting primary and key secondary endpoints and demonstrating competitive, clinically meaningful efficacy.
Shared on 03 Sep 25
Fair value Increased 20%Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
United Therapeutics’ consensus price target has been raised from $380.57 to $399.90, reflecting heightened analyst optimism following positive Phase 3 TETON-2 Tyvaso IPF results that signal a multibillion-dollar sales opportunity and improved revenue outlook despite competitive and litigation risks. Analyst Commentary Bullish analysts increased price targets sharply following "surprisingly positive" Phase 3 TETON-2 results for Tyvaso in idiopathic pulmonary fibrosis (IPF), citing clinically meaningful FVC benefit, strong statistical significance, and a competitive efficacy profile compared to pipeline peers.
Shared on 07 May 25
Fair value Decreased 2.80%Phase III Readouts Will Broaden Pulmonary And Regenerative Markets
Shared on 30 Apr 25
Fair value Decreased 1.71%Tyvaso DPI And FDA Submissions Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Fair value Decreased 1.33%Tyvaso DPI And FDA Submissions Will Open New Markets
AnalystConsensusTarget has decreased shares outstanding growth rate from 0.0% to 0.0%.
Shared on 16 Apr 25
Fair value Increased 0.69%Tyvaso DPI And FDA Submissions Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 6.34%Tyvaso DPI And FDA Submissions Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Decreased 3.62%Tyvaso DPI And FDA Submissions Will Open New Markets
Shared on 26 Mar 25
Fair value Decreased 0.27%Tyvaso DPI And FDA Submissions Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 0.75%Tyvaso DPI And FDA Submissions Will Open New Markets
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 10 Mar 25
Fair value Increased 3.43%Tyvaso DPI And FDA Submissions Will Open New Markets
AnalystConsensusTarget has decreased revenue growth from 9.4% to 7.2%.